DrugDev, Exostar Collaborate on Linked Identifiers
The collaboration will allow joint customers to securely combine data from all site-facing applications using single sign-on with non-site facing data sources.
DrugDev and Exostar will combine their unique global identifiers for clinical operations personnel and facilities to address identity credential duplication and missing or incorrect records in systems.
Exostar offers SAM, a turnkey, cloud-based identity and access management solution that delivers single sign-on application access with multi-factor authentication. DrugDev provides its universal identifier called the DrugDev Golden Number for tracking persons and facilities across multiple data sources. The linkage will allow joint customers to securely combine data from all site-facing applications using single sign-on with non-site facing data sources.
Read the full release.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
